NY-XPANSIV
1.11.2022 14:03:36 CET | Business Wire | Press release
Xpansiv, the premier market-infrastructure platform for environmental commodities, today announced the launch of a new benchmark carbon-offset contract, Sustainable Development Global Emissions Offset™ (SD-GEO™).
The standardized contract, tradable on Xpansiv market CBL, provides a benchmark for market participants and corporates to transact high-quality carbon offsets from projects that also deliver high social impact. The SD-GEO will allow for delivery of cookstove projects with a minimum of five Sustainable Development Goals (SDGs) from the Verra or Gold Standard registries.
Eligible projects are carefully vetted under the CBL Standard Instruments Program that contains the Global Emissions Offset™ (GEO®), the first in this series developed by Xpansiv, as well as the Nature-Based Global Emissions Offset™ (N-GEO®), “widely seen as the frontrunner to become the VCM’s biggest price benchmark,” according to Quantum Commodity Intelligence.
“Corporates often look for offset projects that mitigate emissions while also having co-benefits for local communities—projects like clean cookstoves,” said Russell Karas, Xpansiv Head of Carbon Market Development. “This emerging segment of the carbon market will grow exponentially in the coming years, and Xpansiv offers a better way to price and trade these high-quality credits.”
“The concept of co-benefits is not new to CBL’s standardized offset contracts,” said Xpansiv Chief Commercial Officer Ben Stuart. “The N-GEO, for example, also requires a Climate, Community, and Biodiversity accreditation from Verra. The SD-GEO is the next contract in the GEO series that will bring transparency, price certainty, and a simplified selection process to a vital subset of the offset market—another important step toward a carbon-neutral future.”
“Clean cookstove projects deliver significant sustainable development impact, with our high-quality projects reaching 9–11 SDGs, bringing permanent and measurable improvements to the rural poor,” said Chen Yang, Chief Commercial Officer, C-Quest Capital (CQC). “As one of the leading clean cookstove project developers, we welcome Xpansiv’s initiative, setting a core impact benchmark for this project type and establishing a robust market that will support the future of clean cookstove projects.”
Erik Petersson, Head of Macquarie’s Global Carbon business—an Xpansiv investor and co-marketer of carbon offsets from a suite of CQC cookstove projects—called the launch of the SD-GEO contract a “pivotal moment” in simplifying the path to net zero. “With this contract, organizations can gain transparent, direct market access to high-quality ‘social carbon’ based on standardized metrics while supporting truly impactful projects in these communities,” said Petersson. “We’re excited to support the SD-GEO launch and the opportunities it provides to expand what we can offer our clients more broadly.”
Xpansiv reports the SD-GEO will begin trading on 5 December. The announcement follows the launch of ESGclear from Xpansiv company APX, the leading registry and ledger provider for environmental markets. ESGclear provides unprecedented transparency for transactions that require ESG reporting, financing, and mitigation across supply chains.
About Xpansiv
Xpansiv provides the market infrastructure and data platform for carbon, renewable, and digital-energy commodities. These Intelligent Commodities bring transparency and liquidity to markets, empowering participants to value energy, carbon, and water to meet the challenges of an information-rich, resource-constrained world. The company’s main business units include CBL, the largest spot exchange for ESG commodities, including carbon, renewable energy certificates, and Digital Natural Gas; H2OX, the leading spot exchange for water; XSignals, which provides end-of-day and historical market data; EMA, the leading multi-registry portfolio management system for all environmental commodities; and APX, the leading provider of registry infrastructure for energy and environmental markets. Xpansiv is the digital nexus where sustainability and price signals merge. Xpansiv.com
About C-Quest Capital
C-Quest Capital (CQC) is a world-leading carbon project developer whose purpose is to transform the lives of low-income rural families whose health, well-being, and economic welfare are most at risk from climate change. CQC does this by providing access to clean energy technologies and sustainable land-use solutions that reduce greenhouse gas emissions, combat global climate change, and improve the lives of those in need. CQC was recently awarded “Best Project Developer: Energy Efficiency” and runner-up for “Best Project Developer: Public health” in Environmental Finance’s Voluntary Carbon Market Rankings 2022.
CQC was founded in 2008 and is headquartered in Washington D.C., USA, with subsidiaries in India, Malaysia, Singapore, Cambodia, and Australia and field teams across the countries we operate in. CQC has carbon project operations in over 17 countries across Sub-Saharan Africa, Central America, and South and Southeast Asia. CQC’s Transformation Carbon projects have already reduced CO2 e emissions by 14.62 million tonnes and improved the lives of over 20 million people.
About Macquarie Global Carbon
The “Global Carbon” division of the Commodities and Global Markets group builds on Macquarie’s group-wide energy transition activity and is a continuation of the Group’s 15-year involvement in physical and financial aspects of carbon and environmental product markets around the world. The business provides integrated carbon offsetting solutions across the entire offset lifecycle from generation through to retirement, providing clients with greater access to voluntary and compliance carbon offsets as well as originating, structuring and bringing capital to carbon removal and reduction projects. Find out more at macquarie.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221101005777/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
